Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia

This study aims to understand how a drug called Sonrotoclax responds in people with WM who have either not responded to previous treatment, or their WM has come back after treatment . Researchers aim to see how many patients go into remission after taking the drug, any improvement in symptoms, and what the side effects might be.
Patients will either be given sonrotoclax by itself or in combination with another drug called zanubrutinib, depending on their circumstances. Sonrotoclax is new drug called a BCL-2 inhibitor. It targets a protein called BLC-2 that helps keep cancer cells alive.